Literature DB >> 19444665

Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006.

Carina Marquez1, Samuel J Mitchell, C Bradley Hare, Malcolm John, Jeffrey D Klausner.   

Abstract

While numerous studies examine methamphetamine use and associated risky sexual behaviors in HIV-uninfected individuals, few studies have surveyed HIV-infected individuals in the health care setting. To assess the frequency and trends of methamphetamine use, sexual activity, injection drug use, patient-provider communication, and medication adherence among HIV-infected persons in care, we administered a one-page anonymous survey in 2004 and 2006. The survey was conducted at the two University of California, San Francisco outpatient HIV clinics: at Moffitt Hospital (Moffitt), serving primarily privately insured patients, and at San Francisco General Hospital (SFGH), a county hospital serving primarily patients who are uninsured or publicly insured. In 2006, 39% of men who have sex with men (MSM), 33% of heterosexual men, and 11% of women reported methamphetamine use in the prior 12 months. Methamphetamine use was significantly associated with an increased number of sex partners among MSM and heterosexual men, and poor anti-retroviral medication adherence. Among MSM, methamphetamine use was more common at the SFGH clinic. Between 2004 and 2006, reported methamphetamine use in the last 12 months decreased among MSM at Moffitt (38 to 20%, p<0.01), but increased at SFGH (40 to 50%, p<0.05). Among methamphetamine users we found a high frequency of injection of methamphetamine, which increased at SFGH from 38 to 55%, p<0.05. Patient-provider communication regarding methamphetamine use has increased from 2004 to 2006 but no significant change has been found for providers asking patients about sexual activity. Overall, we found methamphetamine use to be common among HIV-infected patients in care, and associated with an increased number of sex partners, a high frequency of injection drug use, and poor adherence to anti-retroviral medications. These findings support the need for improved screening and clinic-based interventions to reduce and treat methamphetamine abuse and associated high risk sexual behaviors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444665     DOI: 10.1080/09540120802385579

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  51 in total

Review 1.  A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine.

Authors:  Radha Rajasingham; Matthew J Mimiaga; Jaclyn M White; Megan M Pinkston; Rachel P Baden; Jennifer A Mitty
Journal:  AIDS Patient Care STDS       Date:  2011-11-09       Impact factor: 5.078

2.  Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses.

Authors:  Keith A Hermanstyne; Glenn-Milo Santos; Eric Vittinghoff; Deirdre Santos; Grant Colfax; Phillip Coffin
Journal:  Drug Alcohol Depend       Date:  2014-08-05       Impact factor: 4.492

3.  Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings.

Authors:  Saurabh Gupta; Chad A Bousman; Gursharan Chana; Mariana Cherner; Robert K Heaton; Reena Deutsch; Ronald J Ellis; Igor Grant; Ian P Everall
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

4.  Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence.

Authors:  David J Moore; Kaitlin Blackstone; Steven Paul Woods; Ronald J Ellis; J Hampton Atkinson; Robert K Heaton; Igor Grant
Journal:  AIDS Care       Date:  2012-04-24

5.  Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: A pilot randomized clinical trial.

Authors:  David J Moore; Elizabeth C Pasipanodya; Anya Umlauf; Alexandra S Rooney; Ben Gouaux; Colin A Depp; J Hampton Atkinson; Jessica L Montoya
Journal:  Drug Alcohol Depend       Date:  2018-06-21       Impact factor: 4.492

6.  Applying behavioral activation to sustain and enhance the effects of contingency management for reducing stimulant use among individuals with HIV infection.

Authors:  Matthew J Mimiaga; Elizabeth F Closson; David W Pantalone; Steven A Safren; Jennifer A Mitty
Journal:  Psychol Health Med       Date:  2018-09-13       Impact factor: 2.423

7.  HIV among people who use drugs: a global perspective of populations at risk.

Authors:  Jamila K Stockman; Steffanie A Strathdee
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

8.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

9.  Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice.

Authors:  James P Kesby; David T Hubbard; Athina Markou; Svetlana Semenova
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

10.  Improving Adherence to Care Among "Hard to Reach" HIV-Infected Patients in Argentina.

Authors:  Deborah L Jones; Omar Sued; Diego Cecchini; Lina Bofill; Ryan Cook; Mar Lucas; Alejandra Bordato; Isabel Cassetti; Pedro Cahn; Stephen M Weiss
Journal:  AIDS Behav       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.